Clinical trials: Retinal Detachment
Rhegmatogenous Retinal Detachment - Macula Off
A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
The purpose of this study is to evaluate the safety and tolerability of ONL1204 in participants with Macula-off, Rhegmatogenous Retinal Detachment (RRD).
- Trial name
- NCT03780972
- Testing
- ONL1204, Intravitreal Injection, Collection of ocular fluids
- Where
- 4 sites in Australia
- Volunteers
- 14 people
- Sponsor
- ONL Therapeutics
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Vitreomacular Traction
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction.
- Trial name
- NCT00435539
- Testing
- ocriplasmin
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 60 people
- Sponsor
- ThromboGenics
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Rhegmatogenous Macula-off Retinal Detachment
Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.
- Trial name
- NCT00972374
- Testing
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant
- Where
- 6 sites in United States, India and 4 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Proliferative Vitreoretinopathy
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.
- Trial name
- NCT04136366
- Testing
- ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
- Where
- 23 sites in United States
- Volunteers
- 106 people
- Sponsor
- Aldeyra Therapeutics, Inc.